Emory University School of Medicine, Atlanta, Georgia, USA.
Center for Diabetes Metabolism Research Emory University Hospital Midtown, Atlanta, Georgia, USA.
Diabetes Technol Ther. 2021 Sep;23(9):652-660. doi: 10.1089/dia.2021.0107. Epub 2021 Apr 27.
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for CGM coverage required by the Centers for Medicare & Medicaid Services (CMS) ignore conclusive evidence that supports CGM use in various diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the CMS eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.
大量研究表明,连续血糖监测(CGM)在 1 型糖尿病和 2 型糖尿病患者群体中具有临床价值。然而,医疗保险和医疗补助服务中心(CMS)规定的 CGM 覆盖资格标准忽略了支持 CGM 在目前被认为不合格的各种糖尿病患者群体中使用的确凿证据。本文讨论了 CMS 资格标准相对于当前科学证据的局限性和不一致性,并提出了可行的解决方案,以解决这一问题,提高所有糖尿病患者的安全性和护理水平。